ATE483722T1 - Antikrebs-cyclopentaag chinazoline-derivate - Google Patents

Antikrebs-cyclopentaag chinazoline-derivate

Info

Publication number
ATE483722T1
ATE483722T1 AT02755281T AT02755281T ATE483722T1 AT E483722 T1 ATE483722 T1 AT E483722T1 AT 02755281 T AT02755281 T AT 02755281T AT 02755281 T AT02755281 T AT 02755281T AT E483722 T1 ATE483722 T1 AT E483722T1
Authority
AT
Austria
Prior art keywords
alkyl
cyclopentaag
cancer
halogenoalkyl
cyanoalkyl
Prior art date
Application number
AT02755281T
Other languages
English (en)
Inventor
Vassilios Bavetsias
Ann Jackman
Original Assignee
Btg Int Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0121151A external-priority patent/GB0121151D0/en
Priority claimed from GB0129387A external-priority patent/GB0129387D0/en
Application filed by Btg Int Ltd filed Critical Btg Int Ltd
Application granted granted Critical
Publication of ATE483722T1 publication Critical patent/ATE483722T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/90—Oxygen atoms with acyclic radicals attached in position 2 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0215—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing natural amino acids, forming a peptide bond via their side chain functional group, e.g. epsilon-Lys, gamma-Glu

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Non-Alcoholic Beverages (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
AT02755281T 2001-08-31 2002-08-30 Antikrebs-cyclopentaag chinazoline-derivate ATE483722T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0121151A GB0121151D0 (en) 2001-08-31 2001-08-31 Anti-cancer compounds
GB0129387A GB0129387D0 (en) 2001-12-07 2001-12-07 Anti-cancer compounds
US34025301P 2001-12-18 2001-12-18
PCT/GB2002/003979 WO2003020748A1 (en) 2001-08-31 2002-08-30 Anti-cancer cyclopenta[g]quinazoline compounds

Publications (1)

Publication Number Publication Date
ATE483722T1 true ATE483722T1 (de) 2010-10-15

Family

ID=27256270

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02755281T ATE483722T1 (de) 2001-08-31 2002-08-30 Antikrebs-cyclopentaag chinazoline-derivate

Country Status (15)

Country Link
US (6) US7297701B2 (de)
EP (3) EP2332962A1 (de)
JP (1) JP4328202B2 (de)
KR (2) KR100983962B1 (de)
AT (1) ATE483722T1 (de)
AU (1) AU2002321576B2 (de)
BR (1) BRPI0212215B8 (de)
CA (1) CA2458813C (de)
CY (1) CY1111078T1 (de)
DE (1) DE60237902D1 (de)
DK (1) DK1421105T3 (de)
MX (1) MXPA04001905A (de)
PT (1) PT1421105E (de)
WO (1) WO2003020748A1 (de)
ZA (1) ZA200401587B (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4328202B2 (ja) * 2001-08-31 2009-09-09 ビーティージー・インターナショナル・リミテッド 抗癌シクロペンタ［ｇ］キナゾリン化合物
GB0305681D0 (en) 2003-03-12 2003-04-16 Kudos Pharm Ltd Phthalazinone derivatives
US8216582B2 (en) 2006-06-23 2012-07-10 Alethia Biotherapeutics Inc. Polynucleotides and polypeptide sequences involved in cancer
ES2387334T3 (es) 2008-03-18 2012-09-20 Btg International Limited Derivados de ciclopenta[g]quinazolina para el tratamiento de la artritis reumatoide o la leucemia mielocítica aguda
MX336869B (es) 2008-11-03 2016-02-04 Alethia Biotherapeutics Inc Anticuerpos que bloquean espicificamente la actividad biologica de un antigeno de tumor.
WO2012011939A2 (en) * 2010-07-19 2012-01-26 Onyx Pharmaceuticals, Inc. Synthesis of cyclopentaquinazolines
EA201390635A1 (ru) * 2010-12-22 2014-09-30 Оникс Фармасьютикалз, Инк. Эффективные реакции пептидного сочетания и их применение для получения и выделения тринатриевой соли циклопента[g]хиназолина
PL3173427T3 (pl) 2011-03-31 2019-11-29 Adc Therapeutics Sa Przeciwciała przeciwko antygenowi związanemu z nerkami 1 i ich fragmenty wiążące antygen
PT2802351T (pt) 2012-01-09 2019-06-27 Adc Therapeutics Sa Agentes para o tratamento de cancro da mama triplo negativo
GB201707864D0 (en) * 2017-05-16 2017-06-28 Inst Of Cancer Research: Royal Cancer Hospital Platinum-reistant cancer treatment

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2065653B (en) 1979-12-19 1983-03-09 Nat Res Dev Anti-cancer quinazoline derivatives
GB8607683D0 (en) 1986-03-27 1986-04-30 Ici Plc Anti-tumor agents
GB9205320D0 (en) 1992-03-11 1992-04-22 Ici Plc Anti-tumour compounds
GB9223352D0 (en) 1992-11-06 1992-12-23 Ici Plc Tricyclic compounds
GB9408936D0 (en) * 1994-05-05 1994-06-22 Cancer Res Inst Anti-cancer compounds
JPH1166841A (ja) * 1997-08-22 1999-03-09 Mitsubishi Electric Corp 半導体記憶装置
KR100303775B1 (ko) * 1998-10-28 2001-09-24 박종섭 디디알 에스디램에서 데이터스트로브신호를 제어하기 위한 방법및 장치
GB9904275D0 (en) 1999-02-24 1999-04-21 Cancer Res Campaign Tech Anti-cancer compounds
JP3416083B2 (ja) * 1999-08-31 2003-06-16 株式会社日立製作所 半導体装置
JP2002007200A (ja) * 2000-06-16 2002-01-11 Nec Corp メモリ制御装置及び動作切替方法並びにインターフェース装置、半導体集積チップ、記録媒体
JP4328202B2 (ja) * 2001-08-31 2009-09-09 ビーティージー・インターナショナル・リミテッド 抗癌シクロペンタ［ｇ］キナゾリン化合物
ES2373644T3 (es) 2001-08-31 2012-02-07 Btg International Limited Uso de derivados de ciclopenta[g]quinazolina para el tratamiento del c�?ncer.
KR100568546B1 (ko) * 2004-10-19 2006-04-07 삼성전자주식회사 메모리 시스템, 반도체 메모리 장치, 및 이 시스템과장치의 출력 데이터 스트로우브 신호 발생 방법
KR100755371B1 (ko) * 2005-05-03 2007-09-04 삼성전자주식회사 반도체 메모리 장치 및 이 장치의 데이터 스트로우브 신호발생방법

Also Published As

Publication number Publication date
MXPA04001905A (es) 2005-04-19
CA2458813A1 (en) 2003-03-13
US20100216824A1 (en) 2010-08-26
PT1421105E (pt) 2010-12-07
US20040242606A1 (en) 2004-12-02
KR100983962B1 (ko) 2010-09-27
WO2003020748A1 (en) 2003-03-13
DE60237902D1 (de) 2010-11-18
BRPI0212215B1 (pt) 2019-02-19
KR20100043294A (ko) 2010-04-28
US20090023760A1 (en) 2009-01-22
US8552016B2 (en) 2013-10-08
US20100273817A1 (en) 2010-10-28
DK1421105T3 (da) 2010-11-29
US20100056551A1 (en) 2010-03-04
CY1111078T1 (el) 2015-06-11
US7863284B2 (en) 2011-01-04
AU2002321576B2 (en) 2008-09-11
US7297701B2 (en) 2007-11-20
JP4328202B2 (ja) 2009-09-09
JP2005509600A (ja) 2005-04-14
EP1421105A1 (de) 2004-05-26
US7705006B2 (en) 2010-04-27
CA2458813C (en) 2011-11-01
US8063056B2 (en) 2011-11-22
BR0212215A (pt) 2004-09-21
KR20040044511A (ko) 2004-05-28
ZA200401587B (en) 2005-05-25
BRPI0212215B8 (pt) 2021-07-27
EP1421105B1 (de) 2010-10-06
EP2332962A1 (de) 2011-06-15
US8486955B2 (en) 2013-07-16
EP2311850A1 (de) 2011-04-20
US20080015206A1 (en) 2008-01-17

Similar Documents

Publication Publication Date Title
CY1111078T1 (el) Αντικαρκινικες ενωσεις κυκλοπεντα[g]κιναζολινων
CY1112143T1 (el) Χρηση παραγωγων kykλοπenta[g]kinαζολινης για θεραπεια καρκινου
AR057023A1 (es) Compuestos heterociclicos con propiedades inhibidoras de hiv-integrasa
WO2002018383A3 (en) Aza heterocyclic derivatives and their therapeutic use
EP1243582A4 (de) Chinolin- und chinazolinderivate sowie medikamente, die diese enthalten
NO983970D0 (no) Tricykliske forbindelser, deres fremstilling og anvendelse
BR0100318A (pt) Compostos de uracila e uso dos mesmos
BR9913648A (pt) Derivados de quinazolina como medicamentos
ATE416176T1 (de) Kondensierte chinolinderivate und deren anwendung
WO2003106428A8 (fr) Derives d'arylsulfonamides et leur utilisation en tant que antagonistes au recepteur b1 de la bradykinine
WO2002044153A8 (en) 4-6-diphenyl pyridine derivatives as antiinflammatory agents
WO2005115984A3 (en) Large conductance calcium-activitated k channel opener
TW200744575A (en) Methods of treating epileptogenesis
WO1999062909A3 (en) Naphtho- and dihydrobenzo-thiophene derivatives as cytotoxic antitumor agents
DK0759027T3 (da) Bicykliske amidinderivater som inhibitorer af nitrogenoxidsynthetase
ATE261445T1 (de) Neue 1,8-naphtyridin-2(1h)-on-derivate
WO2009135673A8 (en) Compounds with glycidic structure active in the therapy of systemic and local inflammation
BR0114812A (pt) Derivados de 2-pirimidinilóxi-n-aril-benzilamina, seus processos de preparo e uso
NO895023D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive aminderivater.
IL157594A0 (en) Carbamate compounds for use in preventing or treating anxiety disorders
TR200200969T2 (tr) Karbonilamino türevlerinin CNS bozukluklarına karşı kullanılması
PE20010649A1 (es) Derivados de antranilamida de piperidinas 1,4-di-sustituidas como antagonistas muscarinicos
WO2000005224A3 (en) Heterocyclic derivatives and their use as integrin inhibitor
BRPI0418375A (pt) derivados de diaza-espiropiperidina
DE602006020458D1 (de) Carbonsäureamidverbindung und deren verwendung

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1421105

Country of ref document: EP